CING

Cingulate Inc.

Insider Trades

NameValueActionPriceCurrent Price
Werth Peter J.Director
$98k19.5k shares
BuyFeb 6, 2026
$5.04
--
Werth Peter J.Director
$78k15.6k shares
BuyFeb 6, 2026
$5.04
--
Schaffer Shane J.Director, Officer: Chief Executive Officer
$34k6.8k shares
BuyFeb 6, 2026
$5.04
--
Schaffer Shane J.Director, Officer: Chief Executive Officer
$27k5.4k shares
BuyFeb 6, 2026
$5.04
--
Callahan Jennifer L.SVP And CFO
$25k4.9k shares
BuyFeb 6, 2026
$5.04
--
Callahan Jennifer L.SVP And CFO
$20k3.9k shares
BuyFeb 6, 2026
$5.04
--

News

globenewswire.comCingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301globenewswire.comJun 16newsfilecorp.comStonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26newsfilecorp.comJun 4reuters.comUS FDA declines to approve Cingulate's ADHD drugreuters.comJun 2globenewswire.comCingulate Receives Complete Response Letter from FDA for CTx-1301globenewswire.comJun 2globenewswire.comCingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301globenewswire.comMay 14